Strategic Partnerships Capsida maintains high-profile collaborations with AbbVie and CRISPR, signaling validation and potential co-development or licensing opportunities. This suggests sales conversations could focus on joint programs, access to their platform for new targets, and leveraging AbbVie’s and CRISPR’s networks to accelerate partnerships.

Neurology Focus The initial pipeline centers on neurologic diseases with a non-invasive IV delivery approach, presenting a clear entry point for BD discussions with biotech teams targeting CNS and neurodegenerative disorders, including Friedreich's ataxia evidenced by primate data.

Non-invasive Advantage Capsida’s targeted AAV engineering enables systemic delivery with reduced off-target liver exposure, a compelling differentiator for customers seeking safer, less invasive gene therapies and faster clinical translation, potentially expanding interest across rare genetic diseases.

Manufacturing & IP With a state-of-the-art manufacturing facility and an IP portfolio of over 30 patent applications plus issued patents, there is a strong opportunity to discuss licensing, collaboration on manufacturing scale-up, and protection for partner programs leveraging Capsida’s platform.

Clinical Validation Feed Recent conference activity and positive primate data on CAP-004 across heart, sensory nerves, and CNS indicate ongoing clinical momentum. This offers a near-term window for sponsor-pipeline alignment, co-development deals, and accelerated access discussions with potential buyers or co-funding partners.